[0339] Kobayashi K et al, Cytotoxic effects of benzbromarone and its1'-hydroxy metabolite in human hepatocarcinoma FLC4 cells cultured on micro-space cell culture plates. Drug Metab Pharmacokinet. 2013; 28(3):265-8.

[0340] Korff T et al. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J. Cell Biol. 143: 1341-1352 (1998).

[0341] Lyons A B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000 Sep. 21; 243(1-2): 147-54.

[0342] Mathias R A et al, Isolation of extracellular membranous vesicles for proteomic analysis. Methods Mol Biol. 2009; 528:227-42.

[0343] Morales P et al, Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer. J Med Chem. 2015 Mar. 12; 58(5): 2256-64. doi: 10.1021/acs.jmedchem.5b00078. Epub 2015 Feb. 20.

[0344] Morton J J et al, Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. Cancer Res. 2016 Nov. 1; 76(21):6153-6158. Epub 2016 Sep. 1.

[0345] Nakamura et al., Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system. J Biosci Bioeng. 2011 January; 111(1):78-84.

[0346] Neve et al. "A Collection of Breast Cancer Cell Lines for the Study of Functionally Distinct Cancer Subtypes." Cancer cell 10.6 (2006): 515-527

[0347] Oh WK, Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urol Oncol. 2003 May-June; 21(3):229-34.

[0348] Perche F et al, Cancer cell spheroids as a model to evaluate chemotherapy protocols. Cancer Biology & Therapy 13:12, 1205-1213, 2012.

[0349] Phung Y T et al, Rapid Generation of In Vitro Multicellular Spheroids for the Study of Monoclonal Antibody Therapy, J Canc 2: 507-514, 2011.

[0350] Rahman et al. "TRAIL Induces Apoptosis in Triple-Negative Breast Cancer Cells with a Mesenchymal Phenotype." Breast cancer research and treatment 113.2 (2009): 217-230.

[0351] Ramsey S D et al, Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials. 2013 January; 34(1):1-9.

[0352] Reich, M., et al. (2006). "GenePattern 2.0." Nat Genet 38(5): 500-501.

[0353] Rocha N S et al, (2002) Effects of fasting and intermittent fasting on rat hepatocarcinogeneis induced by diethylnitrosamine. Teratog Carcinog Mutagen. 22(2): 129-138.

[0354] Roux S et al, $CD4^{+}CD25^{+}$ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest. 2008 November; 118(11):3751-61.

[0355] Ruggeri B A et al, Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol. 2014 Jan. 1; 87(1):150-61.

[0356] Walker J D et al, Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice. J Virol. 2011 July; 85(14):7363-71.

[0357] Yang S et al, Mouse models for tumor metastasis. Methods Mol Biol. 2012; 928:221-8.

[0358] Zhang C H et al, Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer. J Med Chem. 2015 May 14; 58(9):3957-74. Epub 2015 Apr. 16.

[0359] Zhang F et al, ING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer. Oncotarget. 2015 Jun. 30; 6(18): 16239-52.

[0360] Zhang Y et al, Real-Time GFP Intravital Imaging of the Differences in Cellular and Angiogenic Behavior of Subcutaneous and Orthotopic Nude-Mouse Models of Human PC-3 Prostate Cancer. J Cell Biochem. 2016 November; 117(11):2546-51.

1. A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject adherent stromal cells (ASC), thereby treating a cancer in a subject.

2-6. (canceled)

7. The method of claim **1**, wherein said ASC have been obtained from a three-dimensional (3D) culture.

8. The method of claim **7**, wherein said 3D culture utilizes a medium whose composition is not varied over the course of said 3D culture.

9. The method of claim **7**, whereby a wherein one or more pro-inflammatory cytokines are added to an incubation medium of said 3D culture.

10. The method of claim **9**, wherein said 3D culture comprises: (a) incubating ASC in a 3D culture apparatus in a first growth medium, wherein no pro-inflammatory cytokines have been added to said first growth medium; and (b) subsequently incubating said ASC in a 3D culture apparatus in a second growth medium, wherein said one or more pro-inflammatory cytokines have been added to said second growth medium.

11-12. (canceled)

13. The method of claim **9**, wherein said one or more pro-inflammatory cytokines comprise Tumor Necrosis Factor alpha (TNF-alpha).

14. The method of claim **9**, wherein said one or more pro-inflammatory cytokines comprise Interferon-Gamma (IFN-gamma).

15. (canceled)

16. The method of claim **7**, wherein said 3D culture is performed in an apparatus that comprises a 3D bioreactor.

17. The method of claim **7**, wherein said 3D culture is performed in an apparatus that comprises a fibrous bed matrix, said fibrous bed matrix comprising a synthetic adherent material.

18-22. (canceled)

23. The method of claim **7**, further comprising the subsequent step of harvesting said ASC by removing said ASC from an apparatus wherein said 3D culture was performed.

24. The method of claim **7**, wherein said ASC have been incubated in a 2D adherent-cell culture apparatus prior to said 3D culture.